$
44.010
+0.02(0.045%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
44.755
Open
43.990
VWAP
--
Vol
801.25K
Mkt Cap
2.40B
Low
43.430
Amount
--
EV/EBITDA(TTM)
--
Total Shares
54.53M
EV
2.29B
EV/OCF(TTM)
11.62
P/S(TTM)
1.88
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
347.32M
+7.93%
0.990
+22.25%
331.77M
+4.3%
0.902
+0.27%
332.21M
+4.27%
0.868
-6.63%
Estimates Revision
The market is revising Upward the revenue expectations for LivaNova PLC (LIVN) for FY2025, with the revenue forecasts being adjusted by 1.65% over the past three months. During the same period, the stock price has changed by 18.95%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.65%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.5%
In Past 3 Month
Stock Price
Go Up
up Image
+18.95%
In Past 3 Month
7 Analyst Rating
up Image
43.81% Upside
Wall Street analysts forecast LIVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIVN is 63.29 USD with a low forecast of 55.00 USD and a high forecast of 79.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
up Image
43.81% Upside
Current: 44.010
sliders
Low
55.00
Averages
63.29
High
79.00
Wolfe Research
Peer Perform -> Outperform
upgrade
$60
2025-05-20
Reason
Wolfe Research upgraded LivaNova to Outperform from Peer Perform with a $60 price target. The firm says that since its downgrade, LivaNova's valuation has compressed, its Italian legal overhang has lifted at a total liability a little less than "worst case," and it made a commitment to expand oxygenator capacity into next year, which could produce "step change" in its ability to supply 2026. In addition, management recently sounded "cautiously more-optimistic-than-expected" on the pathway with Medicare for depression, the analyst tells investors in a research note.
Barclays
Equal Weight
downgrade
$56 -> $55
2025-05-08
Reason
Barclays lowered the firm's price target on LivaNova to $55 from $56 and keeps an Equal Weight rating on the shares. The company reported a "robust beat" and its sales guidance was raised, the analyst tells investors in a research note. The firm says LivaNova's Cardio and Epilepsy are on track for a solid 2025 performance.
Baird
NULL -> Outperform
maintain
$55 -> $61
2025-05-08
Reason
Baird raised the firm's price target on LivaNova to $61 from $55 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where they showed a beat and raise and less bad earnings reduction.
Needham
Mike Matson
Strong Buy
Reiterates
$64
2025-03-17
Reason
Barclays
Matt Miksic
Hold
Maintains
$58 → $56
2025-03-07
Reason
Barclays lowered the firm's price target on LivaNova to $56 from $58 and keeps an Equal Weight rating on the shares. The firm updated the company's model to reflect its 2025 guidance and recent commentary.
Goldman Sachs
David Roman
Strong Buy
Maintains
$64 → $55
2025-03-03
Reason

Valuation Metrics

The current forward P/E ratio for LivaNova PLC (LIVN.O) is 11.85, compared to its 5-year average forward P/E of 23.35. For a more detailed relative valuation and DCF analysis to assess LivaNova PLC 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
23.35
Current PE
11.85
Overvalued PE
33.15
Undervalued PE
13.54

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
16.06
Current EV/EBITDA
7.06
Overvalued EV/EBITDA
21.59
Undervalued EV/EBITDA
10.52

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
2.82
Current PS
1.77
Overvalued PS
3.67
Undervalued PS
1.98

Financials

Annual
Quarterly
FY2025Q1
YoY :
+7.44%
316.86M
Total Revenue
FY2025Q1
YoY :
-1076.27%
-311.07M
Operating Profit
FY2025Q1
YoY :
+680.83%
-327.30M
Net Income after Tax
FY2025Q1
YoY :
+670.51%
-6.01
EPS - Diluted
FY2025Q1
YoY :
+267.74%
13.18M
Free Cash Flow
FY2025Q1
YoY :
-0.91%
69.68
Gross Profit Margin - %
FY2025Q1
YoY :
+343.97%
11.41
FCF Margin - %
FY2025Q1
YoY :
+626.44%
-103.30
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
63.7K
USD
1
0-12
Months
69.9K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
31.4K
Volume
2
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
117.0K
Volume
Months
6-9
2
233.2K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

LIVN News & Events

Events Timeline

2025-06-05 (ET)
2025-06-05
08:31:16
LivaNova publishes 24-month data from CORE-VNS study in Epilepsia
select
2025-06-04 (ET)
2025-06-04
08:09:20
LivaNova initiates process with U.S. Centers for Medicare and Medicaid Services
select
2025-05-07 (ET)
2025-05-07
06:26:07
LivaNova lowers 2025 adjusted EPS view to $3.60-$3.70 from $3.65-$3.75
select
Sign Up For More Events

News

8.0
07-17NASDAQ.COM
Interesting LIVN Put And Call Options For September 19th
2.0
06-09NASDAQ.COM
LIVN Makes Bullish Cross Above Critical Moving Average
9.0
06-05Newsfilter
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
Sign Up For More News

FAQ

arrow icon

What is LivaNova PLC (LIVN) stock price today?

The current price of LIVN is 44.01 USD — it has increased 0.05 % in the last trading day.

arrow icon

What is LivaNova PLC (LIVN)'s business?

arrow icon

What is the price predicton of LIVN Stock?

arrow icon

What is LivaNova PLC (LIVN)'s revenue for the last quarter?

arrow icon

What is LivaNova PLC (LIVN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for LivaNova PLC (LIVN)'s fundamentals?

arrow icon

How many employees does LivaNova PLC (LIVN). have?

arrow icon

What is LivaNova PLC (LIVN) market cap?